Testicular Shrinkage: Labs, Causes, and Next Steps

What Testicular Shrinkage Actually Means

Testicular atrophy refers to a measurable reduction in testicular volume below the expected adult range of 15 to 25 mL, as defined by the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism [1]. The testes serve two linked functions: producing sperm (exocrine) and secreting testosterone (endocrine). A decrease in size reflects damage to the seminiferous tubules, Leydig cells, or both.

Size alone does not confirm pathology. Testicular volume varies with age, body habitus, and ethnicity. What matters clinically is a documented decrease from a prior measurement or bilateral volumes below 12 mL on ultrasound. A 2019 meta-analysis published in Human Reproduction Update (N=115,158) found that testicular volume correlates directly with semen parameters and serum testosterone levels, with men in the lowest volume quartile showing a 2.4-fold higher odds of oligozoospermia [2]. Cold exposure, recent ejaculation, and body position can cause transient cremasteric retraction that mimics shrinkage, so measurements should be taken in a warm room with the patient standing.

The Endocrine Society recommends orchidometer measurement during physical exam as a first-line assessment, with scrotal ultrasound reserved for cases where physical exam findings are equivocal or a mass is suspected [1].

Common Causes of Testicular Shrinkage

The differential diagnosis spans hormonal, vascular, infectious, and iatrogenic categories. Each cause leaves a distinct lab and imaging fingerprint, which is why a systematic workup matters more than guessing.

Exogenous testosterone and anabolic steroids remain the most common reversible cause in men under 50. Supraphysiologic testosterone suppresses gonadotropin-releasing hormone (GnRH), which drives FSH and LH to near-zero levels. Without FSH stimulation, the seminiferous tubules involute. A prospective study in The Journal of Clinical Endocrinology & Metabolism showed that men receiving 200 mg testosterone enanthate weekly experienced a mean 25% reduction in testicular volume by week 24 [3]. Recovery after cessation is possible but not guaranteed. Some men require combination therapy with human chorionic gonadotropin (hCG) and selective estrogen receptor modulators (SERMs) like clomiphene citrate to restore the hypothalamic-pituitary-gonadal (HPG) axis.

Varicocele affects the left testicle more often (80 to 90% of cases) due to the perpendicular drainage angle of the left internal spermatic vein into the renal vein. Reflux and venous pooling raise intrascrotal temperature, causing oxidative stress and germ cell apoptosis over time. The American Urological Association (AUA) and American Society for Reproductive Medicine (ASRM) joint guideline states that varicocele repair should be offered when a palpable varicocele is associated with abnormal semen parameters and the couple has documented infertility [4].

Primary hypogonadism (testicular failure) produces low testosterone with elevated FSH and LH. Klinefelter syndrome (47,XXY) is the most common genetic cause, affecting roughly 1 in 660 men according to NIH epidemiologic data [5]. Other primary causes include prior orchitis (mumps-related or bacterial), testicular torsion, chemotherapy exposure (particularly alkylating agents), and prior inguinal or scrotal surgery.

Secondary hypogonadism involves low testosterone with low or inappropriately normal gonadotropins. Pituitary adenomas, hyperprolactinemia, chronic opioid use, and obesity all suppress the HPG axis centrally. The testes shrink not because of intrinsic damage but because they stop receiving the signal to function. This distinction matters because secondary causes are often treatable without lifelong testosterone replacement.

Chronic alcohol use directly damages Leydig cells and seminiferous tubules. A study in Alcoholism: Clinical and Experimental Research demonstrated that men consuming more than 40 g of ethanol daily for over five years had significantly lower testicular volumes and serum testosterone compared to age-matched controls [6].

The Lab Workup: What to Order and Why

A structured lab panel distinguishes primary from secondary causes and identifies reversible contributors. Draw blood fasting, before 10:00 AM, on two separate mornings, because testosterone follows a diurnal rhythm with peak levels in the early morning [1].

Tier 1 (order for every patient):

• Total testosterone. The Endocrine Society defines biochemical hypogonadism as a total testosterone below 300 ng/dL (10.4 nmol/L) on two morning samples [1]. A single low reading is insufficient for diagnosis.
• Free testosterone. Calculated from total testosterone, sex hormone-binding globulin (SHBG), and albumin using the Vermeulen equation. Free testosterone may be low even when total testosterone is borderline, particularly in obese men or those with elevated SHBG from liver disease or aging.
• FSH and LH. These gonadotropins differentiate primary (elevated FSH/LH) from secondary (low/normal FSH/LH) hypogonadism. An FSH above 12 IU/L strongly suggests seminiferous tubule damage [7].
• Prolactin. Elevated prolactin suppresses GnRH pulsatility. Values above 100 ng/mL warrant pituitary MRI to rule out a prolactinoma.
• Estradiol (E2). Elevated estradiol from peripheral aromatization (common in obese men) suppresses LH and accelerates testicular involution.

Tier 2 (order based on Tier 1 results and clinical suspicion):

• Karyotype. Indicated when FSH is markedly elevated (above 20 IU/L) in a younger man with small, firm testes. This is the confirmatory test for Klinefelter syndrome.
• Semen analysis. Assesses the functional impact of atrophy on fertility. The WHO 2021 reference values define a normal sperm concentration as 16 million/mL or higher [8].
• Scrotal ultrasound with Doppler. Confirms testicular volume objectively, identifies varicoceles (retrograde venous flow exceeding 2 mm during Valsalva), and rules out intratesticular masses. The AUA recommends scrotal ultrasound for any palpable testicular abnormality [9].
• Pituitary MRI. Ordered when LH and FSH are suppressed alongside elevated prolactin or clinical signs of a sellar mass (visual field deficits, headaches).
• Iron studies and ferritin. Hemochromatosis deposits iron in the pituitary and testes. Transferrin saturation above 45% with elevated ferritin should prompt HFE gene testing.

Dr. Shalender Bhasin, professor of medicine at Harvard Medical School and lead author of the Endocrine Society's testosterone therapy guideline, has stated: "The diagnosis of hypogonadism requires the presence of symptoms and signs and unequivocally low serum testosterone levels on at least two occasions" [1].

Imaging: When Ultrasound Is Necessary

Scrotal ultrasound is not required for every man who notices size changes. It becomes necessary when the physical exam is inconclusive, when asymmetry suggests a mass, or when varicocele is suspected but not clearly palpable. High-frequency probes (7.5 to 15 MHz) provide millimeter-level resolution of testicular parenchyma.

Ultrasound also quantifies volume more accurately than the Prader orchidometer, which tends to overestimate by 30 to 40% in men with smaller testes [10]. For monitoring atrophy over time (during testosterone therapy, for instance), ultrasound provides reproducible measurements that clinical palpation cannot match.

Color Doppler identifies varicoceles with high sensitivity. A vein diameter exceeding 3 mm with reflux on Valsalva confirms the diagnosis. Ultrasound also detects subclinical varicoceles that are not palpable, though the clinical significance of subclinical varicoceles remains debated.

If ultrasound reveals a hypoechoic mass, tumor markers (AFP, beta-hCG, LDH) and referral to urology are the immediate next steps. Testicular cancer peaks between ages 15 and 35 and can present as atrophy of the surrounding parenchyma rather than a palpable lump.

Treatment Depends on the Cause

There is no single treatment for testicular shrinkage. The correct intervention targets the underlying mechanism.

Stopping exogenous testosterone or anabolic steroids. For men whose atrophy is driven by HPG axis suppression from exogenous hormones, discontinuation is the first step. Recovery is variable. A retrospective cohort study in Fertility and Sterility found that 67% of former anabolic steroid users recovered sperm concentrations above 15 million/mL within 12 months of cessation, but 10% required longer than 24 months [11]. Clinicians may prescribe a restart protocol using hCG (1,500 to 3,000 IU three times weekly) with or without clomiphene citrate (25 to 50 mg daily) to accelerate HPG axis recovery.

Varicocele repair. Microsurgical subinguinal varicocelectomy is the preferred technique, with a recurrence rate below 2% and a complication rate under 1% in experienced hands [4]. A Cochrane review found that varicocele repair improved semen parameters but the evidence for improved live birth rates in subfertile couples remains uncertain [12]. For men with documented ipsilateral testicular atrophy and a palpable varicocele, repair may halt further volume loss.

Testosterone replacement therapy (TRT). When primary hypogonadism is confirmed and fertility is not a concern, TRT restores serum testosterone and relieves symptoms like fatigue, decreased libido, and loss of muscle mass. TRT will not reverse testicular atrophy. It will make it worse, because exogenous testosterone further suppresses intratesticular testosterone production and FSH. The 2018 Endocrine Society guideline explicitly recommends against TRT in men actively seeking fertility [1].

Dr. Peter Schlegel, former president of the American Society for Reproductive Medicine, has noted: "Men who desire future fertility should avoid testosterone therapy entirely and instead pursue targeted treatments like clomiphene or hCG that preserve or restore intratesticular testosterone without suppressing gonadotropin secretion" [13].

Clomiphene citrate for secondary hypogonadism. Used off-label, clomiphene blocks estrogen feedback at the hypothalamus and pituitary, increasing LH and FSH secretion. A study in BJU International (N=400) demonstrated that clomiphene 25 mg every other day raised total testosterone by a mean of 292 ng/dL over 12 months while maintaining or improving semen parameters [14]. This approach preserves testicular volume, unlike exogenous testosterone.

Treating underlying medical conditions. Correcting hyperprolactinemia with cabergoline, managing obesity through GLP-1 receptor agonists or bariatric surgery, discontinuing chronic opioids, and treating hemochromatosis with phlebotomy can all reverse secondary hypogonadism and halt further testicular volume loss.

When to See a Urologist vs. an Endocrinologist

Primary care clinicians can order the initial lab panel and scrotal ultrasound. Referral depends on what the workup reveals.

Refer to urology when: a testicular mass is found on exam or ultrasound, a clinically significant varicocele is present with infertility or progressive atrophy, torsion is suspected (acute onset pain with high-riding testis), or the patient needs surgical intervention such as varicocelectomy or testicular biopsy.

Refer to endocrinology when: lab results suggest secondary hypogonadism with suppressed gonadotropins and no obvious drug cause, prolactin is elevated above 100 ng/mL, pituitary MRI shows an adenoma, or the patient has suspected Klinefelter syndrome or another complex endocrine disorder.

Many men benefit from both specialists. A man with Klinefelter syndrome, for example, needs endocrinology for long-term testosterone management and urology for fertility options such as micro-TESE (testicular sperm extraction).

Lifestyle Factors That Accelerate or Slow Atrophy

Obesity is one of the most modifiable risk factors. Adipose tissue expresses aromatase, which converts testosterone to estradiol. The resulting estrogen excess suppresses LH, reducing intratesticular testosterone production. The EMAS (European Male Ageing Study) found that a 5-unit increase in BMI was associated with a decline in total testosterone equivalent to aging 10 years [15]. Weight loss, whether through lifestyle changes, GLP-1 receptor agonists like semaglutide, or bariatric surgery, can partially reverse this hormonal cascade.

Chronic heat exposure damages spermatogenesis. Occupational exposure (bakers, welders), frequent hot tub use, and prolonged laptop use on the lap all raise scrotal temperature above the 2 to 4°C differential from core body temperature that spermatogenesis requires. These effects are typically reversible within 2 to 3 months of eliminating the heat source.

Sleep matters. Testosterone secretion is pulsatile and linked to sleep architecture. Sleeping fewer than 5 hours per night for one week reduced daytime testosterone by 10 to 15% in a controlled study of young healthy men published in JAMA [16].

Moderate exercise supports testosterone. Resistance training in particular raises acute testosterone levels, though the chronic effect on baseline testosterone is modest. Extreme endurance training (marathon-level mileage) can suppress GnRH pulsatility through the hypothalamic stress response, occasionally causing exercise-induced hypogonadism.

Monitoring After Diagnosis

Once a cause is identified and treatment initiated, follow-up labs and imaging track whether the intervention is working.

For men on clomiphene or hCG restart protocols, check total testosterone, free testosterone, FSH, LH, and estradiol at 6 and 12 weeks, then every 3 to 6 months. Semen analysis at 3 to 6 months assesses fertility recovery. Scrotal ultrasound at 6 and 12 months documents volume changes.

For men on TRT who are not seeking fertility, monitor hematocrit (TRT increases erythropoiesis, and hematocrit above 54% requires dose reduction or phlebotomy), PSA (at baseline, 3 to 6 months, then annually), and lipid panel. Testicular volume will likely continue to decrease on TRT. That expected outcome should be discussed before starting therapy.

For post-varicocelectomy patients, semen analysis at 3 months and scrotal ultrasound at 6 months assess treatment response. Improvement in semen parameters may continue for up to 12 months after surgery.

Men who stop anabolic steroids should have repeat labs at 3, 6, and 12 months. If testosterone remains below 300 ng/dL at 12 months despite cessation, referral to endocrinology for further evaluation is appropriate, because prolonged suppression occasionally causes persistent secondary hypogonadism requiring ongoing treatment.